Rezvoglar (insulin glargine-aglr) / Eli Lilly, Boehringer Ingelheim - LARVOL DELTA

UPTAKE OF BIOSIMILARS TO INSULIN GLARGINE IN 2021-2025 IN THE UNITED STATES (ISPOR 2026) - "Insulin glargine-yfgn (Semglee®) is the first interchangeable biosimilar to Lantus® approved by the U.S. FDA in July 2021. A second biosimilar, insulin glargine-aglr Rezvoglar®), was approved in December 2021 and designated interchangeable status in November 2022... Mild uptake of insulin glargine biosimilars in the insured populations was observed within the first 4 years of marketing in the U.S. Further exploration of factors to access such as provider and patient education, policy implementation, and reimbursement reform is warranted to foster stronger biosimilar adoption."

Diabetes • Metabolic Disorders

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus